S Divisova1,2, E Vlckova1,2, I Srotova1,2, S Kincova1,2, M Skorna2, L Dusek3, P Dubovy4, J Bednarik1,2. 1. Central European Institute of Technology, Applied Neuroscience, Masaryk University Brno, Czech Republic. 2. Department of Neurology, University Hospital Brno, Czech Republic. 3. Insitute of Biostatistics and Analyses, Masaryk University Brno, Czech Republic. 4. Central European Institute of Technology, Cellular and Molecular Neurobiology, Masaryk University Brno, Czech Republic.
Abstract
AIMS: This paper aims to investigate whether intraepidermal nerve-fibre density (IENFD) may be used as a marker of the course of neuropathy in patients with Type 2 diabetes mellitus. METHODS: Skin biopsies from the distal leg were serially evaluated in a group of 30 patients with Type 2 diabetes mellitus (median age 60 years, 17 men) with a short duration of diabetes (< 3 years) and good glucose control, and in 23 age- and sex-matched controls. The time intervals between biopsies were > 2 years (median 33.8 months). Eighteen patients with Type 2 diabetes mellitus had symptoms or signs of distal symmetrical diabetic polyneuropathy, 12 had no neuropathy. RESULTS: At first skin biopsy, IENFD was normal in all controls and in patients without neuropathy (mean 9.5 and 7.9 fibres/mm, respectively) compared with abnormal IENFD in 77.8% in patients with polyneuropathy (mean 3.4 fibres/mm). The annual rate of intraepidermal nerve-fibre (IENF) loss expressed as a percentage of the first IENFD value in patients with diabetic polyneuropathy was significantly higher [mean (se), 11.95 (3.82)%] compared with controls [1.92 (1.81)%, P < 0.001] and similar to patients without polyneuropathy [12.16 (4.38)%]. The rate of IENF loss did not correlate with degree of glucose control. CONCLUSIONS: The annual rate of IENF loss in patients with Type 2 diabetes mellitus was several times higher than that of healthy participants, irrespective of the presence of signs or symptoms of diabetic polyneuropathy at initial evaluation. The change in IENFD is not linear and should be expressed as a proportion of initial IENFD to serve as a marker of the course of diabetic neuropathy.
AIMS: This paper aims to investigate whether intraepidermal nerve-fibre density (IENFD) may be used as a marker of the course of neuropathy in patients with Type 2 diabetes mellitus. METHODS: Skin biopsies from the distal leg were serially evaluated in a group of 30 patients with Type 2 diabetes mellitus (median age 60 years, 17 men) with a short duration of diabetes (< 3 years) and good glucose control, and in 23 age- and sex-matched controls. The time intervals between biopsies were > 2 years (median 33.8 months). Eighteen patients with Type 2 diabetes mellitus had symptoms or signs of distal symmetrical diabetic polyneuropathy, 12 had no neuropathy. RESULTS: At first skin biopsy, IENFD was normal in all controls and in patients without neuropathy (mean 9.5 and 7.9 fibres/mm, respectively) compared with abnormal IENFD in 77.8% in patients with polyneuropathy (mean 3.4 fibres/mm). The annual rate of intraepidermal nerve-fibre (IENF) loss expressed as a percentage of the first IENFD value in patients with diabetic polyneuropathy was significantly higher [mean (se), 11.95 (3.82)%] compared with controls [1.92 (1.81)%, P < 0.001] and similar to patients without polyneuropathy [12.16 (4.38)%]. The rate of IENF loss did not correlate with degree of glucose control. CONCLUSIONS: The annual rate of IENF loss in patients with Type 2 diabetes mellitus was several times higher than that of healthy participants, irrespective of the presence of signs or symptoms of diabetic polyneuropathy at initial evaluation. The change in IENFD is not linear and should be expressed as a proportion of initial IENFD to serve as a marker of the course of diabetic neuropathy.
Authors: Nirupa D Jayaraj; Bula J Bhattacharyya; Abdelhak A Belmadani; Dongjun Ren; Craig A Rathwell; Sandra Hackelberg; Brittany E Hopkins; Herschel R Gupta; Richard J Miller; Daniela M Menichella Journal: J Clin Invest Date: 2018-04-23 Impact factor: 14.808
Authors: Matthew S Yorek; Alexander Obrosov; Hanna Shevalye; Lawrence J Coppey; Randy H Kardon; Mark A Yorek Journal: Neuropharmacology Date: 2016-12-23 Impact factor: 5.250
Authors: Frank L Rice; David Castel; Elizabeth Ruggiero; Marilyn Dockum; George Houk; Itai Sabbag; Phillip J Albrecht; Sigal Meilin Journal: Neurobiol Pain Date: 2018-07-20
Authors: Lawrence Coppey; Eric Davidson; Hanna Shevalye; Alexander Obrosov; Michael Torres; Mark A Yorek Journal: Diabetes Metab Syndr Obes Date: 2020-04-24 Impact factor: 3.168
Authors: Phillip J Albrecht; George Houk; Elizabeth Ruggiero; Marilyn Dockum; Margaret Czerwinski; Joseph Betts; James P Wymer; Charles E Argoff; Frank L Rice Journal: Front Pain Res (Lausanne) Date: 2021-12-08
Authors: Dale S George; Sandra Hackelberg; Nirupa D Jayaraj; Dongjun Ren; Seby L Edassery; Craig A Rathwell; Rachel E Miller; Anne-Marie Malfait; Jeffrey N Savas; Richard J Miller; Daniela M Menichella Journal: Pain Date: 2022-03-01 Impact factor: 7.926